Risks and Benefits of Naloxone Prescribing
Risks and Benefits of Overdose Education and Naloxone Prescribing to Heroin Users
Sponsor: Indivior Inc.
Listed as NCT02535494, this NA trial focuses on Opioid Overdose and remains completed. Sponsored by Indivior Inc., it has been updated 12 times since 2014, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Apr 2022 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Sep 2021 — Apr 2022 [monthly]
Active Not Recruiting NA
-
Feb 2021 — Sep 2021 [monthly]
Active Not Recruiting NA
▶ Show 7 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting NA
-
Jul 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Feb 2020 — Jul 2020 [monthly]
Active Not Recruiting NA
-
Feb 2019 — Feb 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Feb 2019 [monthly]
Recruiting NA
-
Nov 2017 — Jun 2018 [monthly]
Recruiting NA
Phase: PHASE1 → NA
-
Jan 2017 — Nov 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Indivior Inc.
- National Institute on Drug Abuse (NIDA)
- New York State Psychiatric Institute
For direct contact, visit the study record on ClinicalTrials.gov .